What You Should Know:
– Qure.ai, a TIME100 most influential company and global leader in digital healthcare, today announced its collaboration with Microsoft. Qure.ai will onboard its end-to-end lung cancer detection, measurement and management suite of AI-powered solutions onto the Precision Imaging Network.
– This will streamline deployment of Qure.ai solutions to hospitals and health systems across the USA, driving digital healthcare transformation, improved tech integrations and ultimately enhance quality of patient care.
Qure.ai–Microsoft Collaboration: Accelerating Early Diagnosis and Integrated Cancer Care
Qure.ai is a global health technology company advancing early diagnosis and coordinated care through AI-enabled clinical solutions. Its platforms support rapid identification and management of high-burden conditions—including Tuberculosis, Lung Cancer, and Neurocritical emergencies—helping clinicians streamline decision-making, prioritize treatment, and improve patient outcomes. Built for scalability across diverse health systems, Qure.ai’s tools strengthen frontline capacity, enhance clinical accuracy, and enable tighter care coordination.
Qure.ai’s lung cancer suite represents its most advanced innovation to date. Developed using Large Language Models (LLMs) and agentic AI, these solutions bridge radiology, pulmonology, interventional care, and thoracic surgery into a unified workflow—from incidental detection through diagnosis and treatment planning. This integrated pathway addresses one of America’s most urgent oncology challenges: lung cancer remains the leading cause of cancer-related mortality in the U.S., exceeding deaths from colon, breast, and prostate cancers combined.
Jim Mercadante, Chief Commercial Officer at Qure.ai, explains that its collaboration with Microsoft expands access to early detection, automated triage, and real-time tracking for hospitals and health systems. He highlights how this partnership simplifies deployment while strengthening a global alliance network spanning academia, government, industry, and technology. Qure.ai’s long-standing collaboration with AstraZeneca and its role in the EDISON Alliance recently culminated in a five-million-scan milestone across 20 countries—demonstrating how AI applied to routine chest X-rays can reshape earlier lung cancer risk identification at scale.
Today, Qure.ai is deployed in more than 105 countries and 4,800+ clinical sites. It was named a TIME100 Most Influential Company in 2025 for transforming access to diagnosis for high-burden diseases worldwide. With 19 FDA-cleared findings for lung cancer and neurocritical conditions, the company enables clinical precision while catalyzing innovation across the pharmaceutical and life sciences ecosystem.
Its FDA-cleared lung cancer portfolio can be implemented as standalone products or as an integrated suite that creates a cohesive workflow. When deployed together, these tools deliver cumulative operational, clinical, and economic benefits: incidental nodule detection on X-ray (qXR-LN), volumetric quantification on CT (qCT-LN Quant), and longitudinal patient management through qTrack. In parallel, Qure.ai’s neurocritical platform (qER) accelerates triage for emergency findings, supporting rapid, life-saving interventions.
